Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Enlivex Therapeutics Ltd. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ENLV
Nasdaq
2830
www.enlivex.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Enlivex Therapeutics Ltd.
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- Jan 10th, 2025 2:00 pm
Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial
- Dec 12th, 2024 4:29 pm
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
- Dec 11th, 2024 1:30 pm
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
- Dec 5th, 2024 3:49 pm
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
- Nov 26th, 2024 3:15 pm
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000
- Nov 22nd, 2024 5:25 pm
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
- Nov 14th, 2024 1:00 pm
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
- Nov 12th, 2024 1:00 pm
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
- Oct 31st, 2024 4:00 pm
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
- Oct 30th, 2024 12:00 pm
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
- Sep 26th, 2024 12:30 pm
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
- Sep 24th, 2024 12:30 pm
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
- Sep 11th, 2024 4:00 pm
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- Aug 30th, 2024 1:00 pm
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
- Jul 23rd, 2024 12:00 pm
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- Jul 19th, 2024 1:00 pm
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
- Jun 24th, 2024 12:00 pm
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
- Jun 20th, 2024 12:00 pm
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
- Jun 17th, 2024 12:00 pm
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
- Jun 3rd, 2024 12:00 pm
Scroll